Background and Objective: Non-alcoholic fatty liver disease has been identified as a major health -related problem.There is no proven therapy for NAFLD. However, a number of possible treatments have been proposed and studied. The aim of this study was to evaluate the therapeutic effects of both Chlorella Vulgaris and Artichoke leaf extracts on NAFLD.

Materials and Methods: In this clinical trial study, 90 patients with NAFLD participated and randomly allocated to three groups. After initial examination, lipids and liver enzymes were measured. The groups received Metformin, Chlorella supplements and Artichoke. After the therapeutic period, liver enzymes were measured again. All collected data were analyzed using SPSS software and independent T-Test, Mann-Whitney and Chi-Square tests.

Results: At baseline, mean age, systolic and diastolic blood pressure, BMI, ALT, AST, HDL, LDL, TG, CHOL and FBS showed no significant difference in three groups. But, after the completion of the treatment, serum ALT, AST, systolic and diastolic blood pressure and BMI significantly decreased in all three groups.

Conclusion: Our study showed the beneficial effects of Artichoke and Chlorella vulgaris in patients with NAFLD. We suggest future studies be performed with larger sample sizes for precise evaluation of the effects of Artichoke and Chlorella vulgaris on NAFLD.

Background and Objective: In the modern era, nonalcoholic fatty liver disease (NAFLD) is a huge burden on the shoulders of health systems around the world. On the other hand, lack of a specific and effective therapeutic approach has persuaded scientists to look for new treatments, among which probiotics have recently raised interest. The aim of this study was to investigate the effect of probiotics in non alcoholic fatty liver disease treatment.

Materials and Methods: In this randomized clinical trial, 90 patient were enrelled with NAFLD and divided into two groups: 45 patients in the diet and exercise group, and 45 patients received 500 mg/d Familacat capsules in addition to diet and exercise. Then the serum level changes of FBS, Triglycerides, Cholestrol, AST and ALT as well as weight and blood pressure were compared between the groups.

Results: In the FamiLact group, BMI, FBS, cholesterol, LDL, AST and ALT had improved significantly. In the control group, the only insignificantly changed variable was serum LDL. Comparison of the groups showed a significantly better improvement in the FamiLact group in terms of cholesterol and LDL changes. However in the control group, changes in blood pressure and HDL levels were significantly better.

Conclusion: FamiLact is a safe and effective probiotic in improving blood sugar, BMI and lipid profile values (except for HDL) in patients with NAFLD.

Key words: Probiotic, FamiLact, NAFLD